Rebiotix’s prototype index is under development to measure impact of microbiota-based therapeutics on Clostridium difficile infection patient microbiomes
Microbiome samples from the Rebiotix Phase 2 clinical trials will be featured as part of the index development.
Download this press release (381 KB).
ROSEVILLE, MN – March 20, 2019 — Rebiotix Inc., a Ferring company, will present analyses of clinical samples collected during two of the company’s completed phase 2 clinical trials for the prevent of recurrent Clostridioides difficile infection, and the contribution of these data to further develop the company’s prototype MICROBIOME HEALTH INDEX™ (MHI™) platform metric during the Gut Microbiota for Health World Summit. The Summit will take place March 23-24 in Miami, Florida.
“The MHI platform is an integral part of furthering our understanding of the impact of the gut microbiome on human health,” said Dr. Ken Blount, Chief Scientific Officer at Rebiotix. “Through our extensive research programs that have grown from our clinical trials, we are unveiling new facets of the microbiome and its correlation with conditions like Clostrioides difficile infection. We are excited to continue to share our findings with colleagues in the field, as we believe these data are critical to further our collective knowledge concerning the potential of microbiota-based therapeutics.”
The MHI platform, part of the research arm of the company’s microbiota-based MRT™ drug platform, continues to expand opportunities to investigate changes in disrupted gut microbial ecosystem of patients before and after intervention with the MRT drug formulations currently under clinical investigation. Details for the session are as follows:
- Title: Developing Microbiome Restoration Biomarkers for Clostridium difficile Infections: Continued Evaluation of a Prototype MICROBIOME HEALTH INDEX™ Platform
- Date, Time and Location: Saturday March 23, 2019 5:30 PM – 7:00 PM CT in conjunction with the evening reception.
About Rebiotix Inc.
Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionise the treatment of challenging diseases. Rebiotix has a diverse pipeline of investigational drug products built on its pioneering microbiota-based MRT™ drug platform. The MRT platform is a standardised, stabilised drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via ready-to-use and easy-to-administer formats. The lead drug candidate, RBX2660, is currently in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the US FDA for its potential to prevent recurrent C. diff infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized, non-frozen, oral capsule part of a recently completed investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff infection. For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states, visit www.rebiotix.com.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
For more information, please contact:
+1 (651) 705-8774 (direct)